Central nervous system diseases

The treatment of central nervous system diseases has always been mild and cautious, and precise dosage and effective drug delivery efficiency are the main difficulties. For depression, Alzheimer disease, pain and other diseases, we combine high-end preparation technologies such as micro-needling and transdermal drug delivery with advanced technologies such as artificial intelligence, and strive to make important breakthroughs in the treatment of central nervous system diseases.

The difficulty in the treatment of cardiovascular disease is that it is difficult to accurately and effectively deliver drugs to the target site. High-end preparation technology is based on this as the main attack point, and strives to develop and use the most suitable drug delivery method to improve cardiovascular disease. The feasibility and efficiency of treatment.

Metabolic diseases are mostly chronic diseases. Long-term medication or injection brings greater pain to patients. For typical metabolic diseases such as diabetes, we use transdermal patches, microneedles, and long-acting microsphere injection preparations. As the main research and development direction, we strive to develop high-end drug delivery technologies and corresponding products that reduce patient pain and enhance patient clinical compliance.

Micronutrient deficiencies

The focus of supplementing trace elements is to take effective drugs or food for a long time. Most patients have difficulty maintaining good compliance and lead to micronutrient deficiencies. The development and application of high-end preparation technology will focus on ‘one-time use, long-term effectiveness’ as the main direction, through simple administration, long-term maintenance of adequate nutrition, and treatment of trace element deficiency diseases.

Gastrointestinal diseases

The treatment of gastrointestinal diseases should be mild and long-acting. Combined with high-end preparation technology, we will develop more efficient and low-irritating drug delivery technologies and related products.

In the field of end-stage renal disease such as kidney stones, we have combined international advanced technology to develop high-end preparation technologies and products such as laser microspheres, which effectively improve the efficiency and safety of surgery, and reduce the clinical cost of patients.

Immune system diseases

China’s immune system diseases have broad room for development, especially in high-end dressings and advanced drug delivery methods. The aconitum weekly transdermal patch we are developing has low-cost and high-efficiency clinical expectations for the analgesia of cancer, rheumatoid arthritis, mandatory spondylitis and other patients, and is expected to reach more than 3 billion yuan per year sale.